ðã³ããåé¢èšé²ãªãâ€ðšð³äžåœæ¿åº/è¿äºãªã ðºðžCDC/ã¹ãã¿ã³ã»æäœ
â åºåãå€ããŠèŠã¥ããå Žåã¯ãã¡ãã¯ãŠãªããã°ã«ã³ããŒããããŸãã®ã§ãå©çšãã ããã
2026/03/06远èš
ãããã³ããã®éç€ºè«æ±ã¯åºãªãã ãããããã以äžããããã£ãŠãåãâŠããšæã£ãŠé·ãããã®é
ç®ïŒããã·ãŒããHPïŒããã§ãã¯ããŠããªãã£ãã®ã§ãããä¹
ãã¶ãã«èŠããšããéèŠãªãã®ã3ã€äžãã£ãŠããŸãããäžåœæ¿åºãžã®éç€ºè«æ±ãCDCã®ã¹ãã€ã¯ã¿ã³ãã¯èšŒæãªã2ã€ã§ãã

ãã³ããã®ååšèšŒæã¯ãªãã
ããã¯ãã®ãµã€ãããäžçã«åããã¡ãã»ãŒãžã§ãð
ãµã€ã管çè
ã¯ãªã¹ãã£ãŒã³ã»ããã·ãŒããFB

â»ãååšèšŒæããªãããååšããªãããšèšã£ãŠããã®ã§ã¯ãããŸããã
ååšããªãããååšèšŒæããªãã®ã§ãã
ãããçè«çã«ããã£ãäžã§ç¢ºèªã®ããã«è«æ±ããŠããŸãã
ååšèšŒæãšã¯äœãïŒããã¯ç°¡åã«èšããš
ã³ããã®äººð£ïžããã³ããðŠ ãåãåºãããšã§ãã
ãããªèå¿ã®ããšãè¡ãããªããŸãŸããŒã¿ããã°ã©ãããåçãããã¥ãŒã¹çã«ãã£ãŠãªã厩ãçã«ã³ããã¯åšãããšã«ãããŠããã®ã§ãã
ã³ãã以å€ã®ãŠã€ã«ã¹ã¯ãã¡ã
ïŒä»¥äžèšäºã®èš³ïŒ
âãããã³ããžãã¯ç€Ÿã¯ãã¯ãªã¹ãã£ã³ã»ããã·ãŒæ°ãšã®å ±åäœæ¥ã«ããã2023幎7æ21æ¥ã«äžåœã®å ¬åŒããŒã¿ã«ãéããŠãæšæºçãªæ å ±å ¬éè«æ±ãäžåœã«æåºããããšãèªãã«æããŸãã
幞ããªããšã«ãéŠçžå®éžã®äºå宀ã«ã¯äžåœèªã®ç¿»èš³è ãšçç³»ã®å€§åŠçãããã圌ãã¯å¿ èªã®è«æãFarewell to VirologyïŒãŠã€ã«ã¹åŠã«å¥ããïŒããããã«çè§£ããSARS-CoV-2ã®ãçºèŠè ãã§ããããããã³ããžãã¯ãã¥ãŒã¹ã®ã»ã³ã¿ãŒãã©ãŒã«ãã«åœŒã®è£žã®åçãæ²èŒãããŠãããã³ãµã ãªãã¡ã³ã»ãŠãŒåå£«ã«æ å ±å ¬éè«æ±ãå±ãããã£ã³ã¹ã«é£ã³ã€ããŸããã
ç§ã¯éèš³ã«ã圌女ã人é¡å
šäœã«ãšã£ãŠéåžžã«éèŠãªããšãããã°ããã§ãã¯ãªã¹ãã£ãŒã³ã¯ãšãŠãæåã ãšäŒããã¯ãªã¹ãã£ãŒã³ã®åç»ã1æ¬éããŸããã
éèš³ã¯ããŸãã«ãè¡æçã§ãé¡ãçã£éã«ãªããããªããŠãã£ãããããã³ïŒç§ãäžäœäœã«å·»ã蟌ãã ãã ïŒç§ã¯ãã ã®ç¡å¢ãªåäŸãªã®ã«ïŒããšèšããŸãããâ
æ®å¿µãªããã2023幎10æ7æ¥çŸåšãäžåœããã®è¿ä¿¡ã¯ãŸã ãããŸãããããããéèš³ã¯ç§ã«æåãªäžåœã®è«ºãæããŠãããŸããã
ãæ
å ±å
¬éã®æçŽãæã£ãŠæ±ãã䟿åšã«é£ã³èŸŒãããã¿ã¯ãæ±ããŠåºãŠããããªãã
ïŒä»¥äžè«æ±æïŒ
âããã«ã¡ã¯ã
äžè¯äººæ°å ±ååœæ å ±å ¬éæ³ã«åºã¥ããäžè¬èšé²ãžã®ã¢ã¯ã»ã¹ãåžæããŸãã
埩æŠå»çã»ã³ã¿ãŒã«ãããæ°åã³ãããŠã€ã«ã¹ã®çºèŠã«ã€ããŠãããã«ã¯ãFan Wuæ°ãã«ããNatureèªïŒ2020幎3æ12æ¥å·ïŒç¬¬579å·»ã«æ²èŒããããäžåœã«ãããããåŒåžåšçŸæ£ã«é¢é£ããæ°åã³ãããŠã€ã«ã¹ããšé¡ãããç ç©¶ãå«ãŸããŸãã
埩æŠå»çã»ã³ã¿ãŒãææãä¿ç®¡ããŸãã¯ç®¡çããŠãããçŸåšãSARS-CoV-2ããšåŒã°ããæ°åã³ãããŠã€ã«ã¹ïŒãã¹ãŠã®å€ç°æ ªãå«ãïŒã«é¢ãããã¹ãŠã®ç ç©¶ããéããã ããããã ããèšåºæ€äœã¯ä»ã®éºäŒç©è³ªïŒãµã«ã®è è现èãå¥åVero现èããŠã·èå è¡æž ãªã©ïŒãšæ··åãããŠããªãç¶æ ã§ãææãã宿䞻ããæ¡åãããæ€äœããåŸããããã®ã§ãªããã°ãªããŸããã
æè¬ããŸããã¯ãªã¹ãã£ãŒã³ã»ããã·ãŒâ
â»èšäºèš³ãããŸã§
ã»ã埩æŠå»çã»ã³ã¿ãŒã«ãããæ°åã³ãããŠã€ã«ã¹ã®çºèŠã«ã€ããŠã
ããã¯æåã®Natureè«æãæããŸãã
ã»ãŸãäžç·éšã¯çްèå¹é€ã§ãªãææè
ã®æ€äœããåé¢ïŒç²Ÿè£œ/åé¢ïŒãããŠã€ã«ã¹ã§ããããšãæå³ããŸãã
ïŒåèïŒGrokã«äžåœã®æ å ±å ¬éå¶åºŠã«ã€ããŠèããŸããã
ðºðžCDCïŒç±³çŸç
äºé²ç®¡çã»ã³ã¿ãŒïŒ2023/03/21ãNew!
è«æ±ïŒæ°åã³ããã¯ã¯ãã³æ¥çš®ã«ããã¹ãã€ã¯ã¿ã³ãã¯è³ªãšæäœã®ç¢ºèªèšé²
ãèŠã€ãããŸããã§ããã
è«æ±å 容ã¯ãã®ãããªæãã§ãð
â ã¯ã¯ãã³æ¥çš®ã«ããäœå ã§çæãããã³ããã®ã¹ãã€ã¯ã¿ã³ãã¯ãšãæªæ¥çš®è ïŒææè ïŒã®äœå ã«ååšããïŒã¯ãã®ïŒå€©ç¶ã®ã¹ãã€ã¯ã¿ã³ãã¯ã®ååšç¢ºèªã»æ¯èŒèšé²ã
â¡æ¥çš®ã«ããäœå ã§çæãããã¹ãã€ã¯ã¿ã³ãã¯ã«ããæäœãç£çããããšãã話ã§ãããããã®æäœãä»ã®ã¯ã¯ãã³ã«ããä»ã®ãŠã€ã«ã¹ã«å¯Ÿããæäœãšæ¯èŒããèšé²ã
æ¥çš®ã«ãã£ãŠã§ãããšããã¹ãã€ã¯ã¿ã³ãã¯ãæäœã確èªãããããšããªããšããããšã«ãªãã°ãã¯ã¯ãã³ã®ãã®å¹èœæžãæå¹æåã¯ãã¿ã©ã¡ãšããããšã§ãã倧åé¡ã§ãïŒç¬
ãŸããŠã€ã«ã¹èªäœããŠãœãªã®ã§çµå±ãããªã£ãŠããŸãããã§ããããããªãã®ãæã£ãæããªãã§å€§éšãããŠããæä»£ããã£ããšããããšã§ãã人é¡ã®é»æŽå²ã§ãã
ðºðžCDCïŒç±³çŸç
äºé²ç®¡çã»ã³ã¿ãŒïŒ2023/03/02ãNew!
è«æ±ïŒSARS-COV-2ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ååšèšŒæ
ãèŠã€ãããŸããã§ããã
â 質å4)ã§ã³ããã®ã现èå¹é€ãã«ã€ããŠéåžžã«çããšãããçªããŠããŸãw
ããªãããã®èºçµç¹ã䜿ããªãã®ã§ããããïŒ SARSã¯ïŒããã®ïŒåŒåžåšç³»ã®ç æ°ã§ãããïŒãµã«ã®ïŒè èã®ç æ°ã§ã¯ãããŸãããã
CDCã¯ããã®è³ªåã¯è«æ±ã®åœ¢åŒãšããŠäžé©åœã§ããããšããŠçããŠããŸããã
äžåœã®ã©çãäžã§ã³ãŠã¢ãªðŠãããããããšãããæªç¥ã®èºçãŠã€ã«ã¹ãã
ãªãããããã¢ããªã«ã®ãµã«ã®è èã§ããå¢ããããšããããšãããã£ãã®ã§ãïŒå€±ç¬ðïŒ
ðªðºæ¬§å·CDCïŒçŸç
äºé²ç®¡çã»ã³ã¿ãŒïŒ2023/03/07
è«æ±ïŒSARS-COV-2ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®çºèŠã»ç²Ÿè£œèšé²
ãä¿æããŠããŸããã
ãã®åŸãéºäŒåã¯ä»®èª¬ã§ããããšããããšãããããmRNAèªäœãæªãããªã£ãŠããŸããã
ãããšããŸæ¥æ¬åå°ã«å»ºèšäžã®mRNAã¯ã¯ãã³å·¥å ŽããããŠç¶ã éçºäžã®mRNA/ã¬ããªã³ã³ã¯ã¯ãã³ãšã¯äžäœïŒ
â»åç®äžmRNAã¯ã¯ãã³ã«ããããšã«ããã補é ã®æéãæéãè²»çšã现èå¹é€ãªã©ãå¿ èŠãšããåŸæ¥åã¯ã¯ãã³ã«æ¯ã¹å€§å¹ ã«ã«ããã§ããã¡ãªããã¯ãããšæãããŸãã
éºäŒåã仮説ãªãDNAããããŠæ¶ç©ºã®ãã®ãªããã§ãäžææéšãããDNAæ··å ¥åé¡ããŠãœã ãšããããšã«ãªããŸãã
ãã®èŸºã¯ä»ã®ç§ã®æã«ã¯è² ããªãäºé ãªã®ã§ã誰ãã®è§£æãåŸ ã¡ãããšæããŸãã
ïŒã¯ããœã³ãšã¯ãªãã¯ãã§èª¿ã¹ããšæããããã€ãããããâŠïŒïŒ
ãšã«ããæããªãããšãããã ãã§ãã
åé¡ã¯ã³ããã¯ã¯ãã³ã
ãäœå
ã§ç£çãããã¹ãã€ã¯ã¿ã³ãã¯ã«ããæäœãå
ç«ãã§ããææçã®äºé²ãã§ããã
ãšãããŠããããšã§ãå¹èœã«ãŠãœãæžããŠãããšããããšã«ãªããŸãã
ãã¡ã1ããã¡ã2
ææçå°éå»ïŒå¿œé£è³¢å¿ïŒãè§£èª¬ïŒ åãã£ãŠããã¯ã¯ãã³ã®å¹æãšå¯åå¿
æ¹ããŠã¹ãã€ã¯ã¿ã³ãã¯ãšã¯ïŒ
CGãã€ã©ã¹ãã§ãããã説æãããŸãã

ãåçãã§èŠããšããã§ãïŒç¬ïŒ
äžåœã§æåã«çºè¡šãããéºäŒåé
å衚ãããã®ãã²ãã²éšåã®é
åãç¹å®ãããã®ãã²ãã²ã®ã¿ã³ãã¯è³ªãç§ãã¡ã®äœå
ã§äœãé
åïŒmRNAïŒãäœæãå°å
¥ããã®ãä»åã®ã¯ã¯ãã³âŠ
ãšãã話ã ã£ãã®ã§ããããããªã¿ã³ãã¯è³ªã®å®ç©ã¯ãªããšããããšã§ãã
ãããããŠã€ã«ã¹èªäœããªãããã§ããã
ãšãªãã°ã³ããã¯ã¯ãã³ã®mRNAã¯å°ãªããšããã®ã©ã¡ããã§ãã
â ã¹ãã€ã¯ã¿ã³ãã¯ã§ã¯ãªãå¥ã®äœãïŒæ¯ç©ïŒãäœã£ãŠãã
â¡äœãäœã£ãŠããªã
ã»çããšããªããªãã®ã§ãããmRNAèªäœããŠãœã§ãããªãã®ã¯å
¥ã£ãŠããªãïŒéºäŒåãšããèãã¯ä»®èª¬ã«éããªãïŒãšãã話ããããŸãã
ããã ãšãã¯ã¯ãã³èãããã·ã§ãã£ã³ã°ãã®å
ãšãªãç©è³ªã¯mRNA以å€ã®ãã®ãäœã£ãŠããããšã«ãªããŸããã
ããã¯åããèŠãŠããçŽ äººã«ã¯ããããªãåé¡ã§âŠãšã«ããæããªãããšã§ãã
ã³ããã¯ã¯ãã³ã®mRNAããŒã¿ã¯ãã¡ãã®åé ã«ð
ãå
¬è¡šæåã ãã§ååå±éºããã¡ã€ã¶ãŒ,ã¢ãã«ã,ã¿ã±ã
ð¬ð§NHSã°ã©ã³ãã¢ã³ïŒè±åœå¶å»çãµãŒãã¹/ã¹ã³ããã©ã³ãïŒ2023/01/05
è«æ±ïŒCOVID-19ãŠã€ã«ã¹ïŒå€ç°æ ªãå«ãïŒã®åé¢ïŒç²Ÿè£œ/çŽç²åïŒã«é¢ããäžçäžã®ç ç©¶ãå ±å
ãä¿æããŠããªãããšããç¥ããããŸãã
ãã®ããã«COVID-19æ
å ±ããŒãžãããã®ã«äœãä¿æããŠããªãããã§ãã
ðºðžCDCïŒç±³çŸç
äºé²ç®¡çã»ã³ã¿ãŒïŒ2023/02/14
è«æ±ïŒSARS-COV-2ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®çºèŠã»ç²Ÿè£œèšé²
ãèŠã€ãããŸããã§ããã
ååããŸããããã®ã§å床ååãã
ä»åã¯ã¹ãããªãšããåçãã³ããã®ã¹ãã€ã¯ã¿ã³ãã¯ãªã©ååšããªãã®ã§ãã
ããŠãããªããšãèª¬ææžã«ããã¯ã¯ãã³ã®å¹èœãæå¹æåã®èšèŒã¯ãŠãœã«ãªããŸãð
ããã ããèŠãŠãæã£ã人ã¯ã ãŸãããã®ã§ããïŒèªãã§æã£ãŠããã°ã®è©±ã§ããïŒ
ãã ååŽçããããã»ã»ã»ãšèããããŠããŸãããšè²¬ä»»åé¿ã§ããããçµã°ããŠããŸãã
ã€ãŸãååŽçã®åœ¹äººã¯äºå®ãç¥ã£ãŠããã®ã§ãããã
ã€ãŸããã®ãå»è¬åãã®èª¬ææžã«ã¯
ããã®æ³šå°ã¯ïŒãããããªãïŒã¹ãã€ã¯ã¿ã³ãã¯è³ªãäœå
ã§äœã£ãŠããªããç
æ°ããå®ããŸãã
ãšããè¶£æšã®ããšãæžãããŠããããã§ãããã¯å€§åé¡ã ãšæããŸãã
ãããæç¢ºã«ããã®ãä»åã®éç€ºè«æ±ã§ãã
æã£ã人ããç°èããããšããå ±åãããããããã®ã§ãã¹ãã€ã¯ã¿ã³ãã¯ã§ã¯ãªãäœãã®ç°ç©ãäœå ã§äœãããŠã¯ããã®ã§ãããã
ðºðžCDCïŒç±³çŸç
äºé²ç®¡çã»ã³ã¿ãŒïŒ2022/12/16
è«æ±ïŒSARS-COV-2ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®çºèŠã»ç²Ÿè£œèšé²
åçïŒã質åãæžãæãç¡é¢ä¿ãªåçã
ããã¯1éç®ã®è¿äºã§ãð
ã¹ãã€ã¯ã¿ã³ãã¯ã®ç²Ÿè£œã«ã€ããŠèããã®ã«ååèããããŠã€ã«ã¹ã®çްèå¹é€ããã®ç²Ÿè£œãã«è³ªåãå€ããããŠããŸããåçã¯ãã®æãšåããã®ã§ãã
ã€ãŸããã¹ãã€ã¯ã¿ã³ãã¯ã¯ååšãããã§ããïŒããšèãããšãã
ããŠã€ã«ã¹ã®ååšã«ã€ããŠã®è³ªåã§ãããã¯ããšã£ãŠãæããã§ããïœã
ãšããè¿çãè¿ã£ãŠãããããªæãã§ãã
質åè ã¯ãªã¹ãã£ãŒã³ã»ããã·ãŒããã®åäžã®æè°ã«ãããããããCDCã¯äœãšèš3ååãå 容ã®è¿çãããããŸãïŒéäžã¯ãªã¹ãã£ãŒã³ããã«å¯Ÿããã©ããééã£ãŠãããããããŸãããïŒããªã©ãšéãçŽãå Žé¢ããããŸãïŒã
ãããŠ4éç®ã®è¿äºã§ããããèããã質åãèŒããŸããð
ãããããã«å¯Ÿããåçã¯ãããŸã§ã®éã質åã«å¯Ÿãããã®ãšåãã ã£ããšããâŠ
ãããCDCã®ããããšã§ãã
æµ·å€ã®æ
å ±å
¬éè«æ±ã§ã¯ãè¡æ¿ææžã¯ä¿æããªããã䜿ããªãã®ã§ãæ¬åœã«çããããªã質åã¯ãã®ããã«ããŸãããšããããšã§ãããã
ã¹ãã€ã¯ã¿ã³ãã¯ãååšããªãããšãèªããã®ã¯ããããããšãŠã€ã«ã¹ã®ãã以äžã«åœŒãã«ãšã£ãŠã¿ããŒãªã®ãããããŸããã
CDCãæ¥æ¬ã«æ¥ããæ¥æ¬èªã§è³ªåæ»ãã«ãããšææç ã«èãããã¯é¢çœãåçãåŸããããã§ãã
æ¹ããŸããŠãããã¹ãã€ã¯ã¿ã³ãã¯ã§ãð

æ¬äœã®ã³ãããååšããªãã®ã§åœç¶ãã®ãã¹ãã€ã¯ã¿ã³ãã¯ãããããŸããã
ãªã®ã§ã¯ã¯ãã³ã«ãã£ãŠæ¥çš®è
ã®äœå
ã§äœãããã®ã¯ãè¬ã®ã¿ã³ãã¯è³ªãâ»
ãããéç§°ãã¹ãã€ã¯ã¿ã³ãã¯è³ªããšãªã£ãŠããããã§ãã
â»ã¿ã³ãã¯è³ªãªã®ããããããŸããããäœã«äžèŠãªãè¬ã®ç°ç©ããšèšãã°ééããªãããã§ãã
ã€ãŸããã®èª¬æðã¯ãã¹ãŠç©ºæ³ã®ç©èªãšããããšã«ãªããŸãã
ãªã®ã§ãåŸæã®ãèããããŠããŸããã§ç· ãããã£ãŠããã®ã§ãã
New!
ðºðžCDCïŒç±³çŸç
äºé²ç®¡çã»ã³ã¿ãŒïŒ2022/11/17
è«æ±ïŒçްèå¹é€ð§«ããSARS-COV-2ðŠ ã粟補ããèšé²
åçïŒãã¯ããããã
ãããŸã§ã®è«æ±ã¯æ£è
ã®æ€äœð£ïžããçŽæ¥ðŠ ãåãåºããèšé²ã§ããã
ããã¯äžçã®ã©ãã«ããªãã£ãããã§ãããä»åã¯è³ªåãå€ããŠ
ããŠã€ã«ã¹åŠã§ "åé¢"ã§ãããšãããŠãã现èå¹é€ã
ð£ïžïŒðïŒðïŒðâð§«
ãã®ð§«ããðŠ ãåãåºããããšã¯ããã®ãïŒãšãããã®ã
ãã®åçããããã«èšé²ã¯ãªããšããããšã§ãããåçãã¯ããããããããšã«å¯Ÿãããã·ãŒããã¯ççã«æè°ããæ£åŒã«ãèšé²ãªããåçãåºãããèŠæ±ããŠããŸãã
ã§ãããCDCããã®è¿äºã¯ãåçã«äžæºãããã°ããã«å¥ã®æ©é¢ã«èšŽããŠãã ããããšãããã®ã§ããã
â
åæ§ã®ããšã¯ãã€ãð©ðªããã«ãã»ã³ããç ç©¶æã2020/09/04ã«ã¯ã£ããåçããŠããŸãã
ã³ããåé¢/çŽç²åèšé²ãªãðâ¡âãã®äžãã13çªç®
ã现èå¹é€ð§«ããSARS-CoV-2ðŠ ã粟補ïŒåé¢ã»çŽç²åïŒããè«æãç¥ããŸããã
现èå¹é€ã¯ãŠã€ã«ã¹åé¢ã®ãæšæºçãªææ³ããã€ãŸããŠã€ã«ã¹åŠã®äžçã§ãåé¢ããšèšãæãããã¯å¿
ãã现èå¹é€ããæããŠããŸãã
çšèªã®æå³ãå€ããããŠããããšã«ã泚æãã ããã
ãã®ãåé¢ããšåŒã°ãã现èå¹é€ã«ã€ããŠð
ïŒãŠã€ã«ã¹ã®ååšã蚌æããå¯äžã®æ¹æ³ãšãªã£ãã®ã§ãã
匷調ãããã®ã¯ããã®æé ã¯ãŠã€ã«ã¹åŠè
ããŠã€ã«ã¹ã®ååšã蚌æãããããã€ãããæ¹æ³ã®äžã®ã²ãšã€ã§ã¯ãªãããšããããšã§ãã
ãå¯äžãã®æ¹æ³ãªã®ã§ãã
ãã®å¯äžã®æ¹æ³ã§ãã现èå¹é€ð§«ïŒãã®äžã«ãŠã€ã«ã¹ãå«ãŸããŠãããšäž»åŒµãã现èå¹é€ð§«ããðŠ ãåãåºããããšã¯ãªããšããäºå®ã
ã€ãŸã现èå¹é€ð§«ãããããåé¢ããšåŒãã ãšããã§ãŠã€ã«ã¹åŠè
ã¯å®ç©ã®çŽç²ãªãŠã€ã«ã¹ðŠ ãæã«ããããšã¯ãªããããã«ãããŠã€ã«ã¹åŠã®æ¯ã®æ ¹ã¯æ¢ãŸããŸããã
å®ç©ã®çŽç²ãªãŠã€ã«ã¹ðŠ ããªããã°åçã«ãåããªãããéºäŒåè§£æãäžå¯èœã
æ€æ»æ³ãæ²»çæ³ãã¯ã¯ãã³ãéçºããããšã¯ã§ããªãã®ã§ãã
ãã¡ãããã®ãå€ç°æ ªãã®ååšã確èªã§ããŸããã
ïŒåèïŒãã¿ã¯ã¯ãã³ã®è£œæ³ð
ãåŸããŠã€ã«ã¹æ¶²ã粟補ããšãããŸãããããã¯ã»ãŒèåœèª¬æãšããããšã«ãªããŸãã
â»ãã®ä»å€ãã®ã¯ã¯ãã³ã®æ·»ä»ææžã«åæ§ã®èšè¿°ããããŸãã
ãã è©åŒã§ãã£ãŠããŠã€ã«ã¹æ¶²ã粟補ããããšèšãããšã¯å¯èœã§ãã
ãŠã€ã«ã¹ç ç©¶ã®å Žã§ã¯ãã®æ··åç©ð§«ãããŠã€ã«ã¹æ¶²ããšåŒãã§ããã®ã§ããåŸããŠã€ã«ã¹æ¶²ð§«ãããéå€ãªäžçŽç©ãåãé€ãã°ããšããããããŠã€ã«ã¹æ¶²ã粟補ãããããšã«ã¯ãªããŸãã
ãã ãããã¯ð§«ããðŠ ãåãåºãããšããããšã§ã¯ãããŸããã
â»çšèªã«ã€ããŠ
æ¬æ¥ã¯ããã§ãð
åé¢ïŒåé¢ïŒçŽç²åïŒç²Ÿè£œ
ãã®äžã§åé¢ã ããŠã€ã«ã¹åŠã®äžçã§ã¯çްèå¹é€ïŒð£ïžïŒðïŒðïŒðâð§«ïŒãšå®çŸ©ãããŠããŠããã®ããšã話ããããã«ããããŠããŸãã
ãã³ããã®ååšèšŒæã«è³é150äžãŠãŒãïŒ2ååïŒããã€ãã®ãµã€ãã§ãðãâ»çµäºããŸãã
ã声æããäžéšèš³ã
â ç§ãã¡ã¯æ°ã¥ããŸãã
ãŠã€ã«ã¹åŠè
éã¯SARS-CoV-2ãªã©ã®ç
åãŠã€ã«ã¹ãååšãããšäººã
ãã ãŸããŸããã
â¡ç§ãã¡ã®ç®æš
å»åŠã¯çŸå®ããé ãé¢ããçã®å¥åº·ãžã®çè§£ã倱ãããŸããã
ç§ãã¡ã¯äººã
ãç
æ°ãå¥åº·ãžã®çè§£ãæ·±ããããã®è²¢ç®ãããŠãããããšèããŠããŸãã
â¢ç§ãã¡ã¯ä¿èšŒããŸã
ã³ããååšã®ç§åŠç蚌æ ãæäŸãããŠã€ã«ã¹åŠè
ã«150äžãŠãŒãé²åã
蚌æ ã«ã¯ãã®äœè£œã®ããã®ãã¹ãŠã®æé ãææžåãããã®ãå«ã¿ãŸãã
â»ãŠã€ã«ã¹åŠè
ã¯èªç§°ãªã®ã§èª°ã§ãå¿åå¯ã ãšæããŸãã
ã³ããã®ååšèšŒæãã§ããã»ã©ã®äººãªã誰ã§ãç«æŽŸãªãŠã€ã«ã¹åŠè
ã§ãã